11 results
PocketPEM - Resus Meds
#Management #Pharm	#Peds #EM	#Resus #Medications #ResusMeds #Resuscitation #PocketCard #PocketPEM
PocketPEM - Resus Meds ... #Management #Pharm ... #Peds #EM #Resus
Classes of Mutations in the Gene Encoding Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). Depending on the
molecular defect, CFTR ... no functional CFTR ... #Pharm #Pathophys ... #Pulm #Peds #CysticFibrosis ... ModulatorTherapy #NEJM
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del #EBM #CysticFibrosis #Tezacaftor #Ivacaftor #CFTR #Phe508del #NEJM
for Phe508del #EBM ... Tezacaftor #Ivacaftor #CFTR ... #Phe508del #NEJM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... - ICU FOCUS - NEJM ... UGIB TRISS - NEJM ... unnecessary and cause harm ... /vmoitra) #EBM
Mortality after Fluid Bolus in African Children with Severe Infection - June 30, 2011 N Engl
NEJMoa1101549 #EBM ... #Peds #Pediatrics ... Boluses #Africa #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Effect of Tolvaptan on the Estimated Glomerular Filtration Rate (GFR). #EBM #Nephro #Pharm #Tolvaptam #PCKD #PolyCysticKidneyDisease
#EBM #Nephro #Pharm ... PolyCysticKidneyDisease #NEJM
Long-Term Effects of Inhaled Budesonide for Bronchopulmonary Dysplasia #EBM #Peds #Budesonide #BronchopulmonaryDysplasia #BPD #VisualAbstract #NEJM
Bronchopulmonary Dysplasia #EBM ... #Peds #Budesonide ... VisualAbstract #NEJM
Pediatric asthma pathway. #EM #Peds #Management #Pharm #Asthma #PediatricAsthma #StatusAsthmaticus
#EM #Peds #Management ... #Pharm #Asthma
PocketPEM - Drips #Management #Pharm #Peds #EM #PICU #Gtt #Drips #PocketCard #PocketPEM
Drips #Management #Pharm ... #Peds #EM #PICU